| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
As a beta-lactam antibiotic, Cefpirome sulfate targets penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. By binding to and inhibiting these PBPs, it disrupts the final stages of bacterial cell wall synthesis, specifically the cross-linking of peptidoglycan chains. This leads to the formation of defective cell walls, osmotic instability, and ultimately bacterial cell lysis and death. Its fourth-generation status confers activity against a broader spectrum of organisms, including some that produce beta-lactamases.
|
|---|---|
| ln Vitro |
In vitro, Cefpirome sulfate demonstrates broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. It is effective against staphylococci, penicillin-resistant pneumococci, and enterococci. Its activity is typically assessed using standard susceptibility testing methods, such as broth microdilution or disk diffusion, to determine the minimum inhibitory concentration (MIC) against various bacterial pathogens.
|
| ln Vivo |
In vivo, Cefpirome sulfate is used to treat a variety of bacterial infections. Its broad spectrum of activity makes it a valuable option for empiric therapy of severe infections. It is particularly noted for its efficacy against Pseudomonas aeruginosa. The compound is also used in research to study bacterial resistance mechanisms and to evaluate the efficacy of new antibiotics.
|
| Enzyme Assay |
For in vitro antibacterial susceptibility testing, standard procedures recommended by the Clinical and Laboratory Standards Institute (CLSI) are followed. Bacterial strains are cultured and suspended to a 0.5 McFarland standard. The suspension is inoculated onto Mueller-Hinton agar or into broth containing serial two-fold dilutions of Cefpirome sulfate. After incubation, the MIC is determined as the lowest concentration that inhibits visible bacterial growth.
|
| Cell Assay |
For in vitro cell-based assays, the antibacterial activity of Cefpirome sulfate can be evaluated using cell culture models of infection. Mammalian cell lines are infected with bacterial pathogens in the presence of varying concentrations of the antibiotic. After incubation, bacterial counts are determined. Cytotoxicity to mammalian cells is assessed using standard assays.
|
| Animal Protocol |
For in vivo animal studies, Cefpirome sulfate is typically administered parenterally in rodent models of infection. The compound's efficacy is evaluated against systemic or localized infections caused by susceptible pathogens. Parameters such as survival rates, bacterial load in tissues, and clinical signs are assessed. Pharmacokinetic studies are also performed.
|
| ADME/Pharmacokinetics |
Cefpirome sulfate is soluble in DMSO (44 mg/ml). It is typically stored at 2-8°C. It has a melting point of 198-202°C. As an antibiotic, it is administered parenterally. Detailed pharmacokinetic parameters are available in the literature.
|
| Toxicity/Toxicokinetics |
As a fourth-generation cephalosporin, Cefpirome sulfate is generally well-tolerated. However, like other beta-lactam antibiotics, it can cause allergic reactions in sensitive individuals. It is used in clinical settings and is not intended for research use in humans.
|
| Additional Infomation |
Cefpirome sulfate is a nitrogen-containing heterocyclic sulfate with functions similar to Cefpirome. Cefpirome sulfate is the sulfate form of Cefpirome, a semi-synthetic broad-spectrum fourth-generation cephalosporin with antibacterial activity. Cefpirome binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. PBPs are enzymes involved in the final stages of bacterial cell wall assembly and in remodeling the cell wall during bacterial growth and division. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is crucial for maintaining the strength and rigidity of bacterial cell walls. This leads to weakening of the bacterial cell wall, ultimately resulting in cell lysis. Cefpirome is a fourth-generation cephalosporin antibiotic. In vitro studies have shown that Cefpirome is more active against Staphylococcus, certain Enterococci, certain Enterobacteriaceae, and Pseudomonas aeruginosa. The cephalosporin core of Cefpirome has a pyridine group attached to the C-3 position.
Cefpirome sulfate is a clinically used antibiotic for the treatment of bacterial infections. It is not typically used as a research compound, but it may be used as a reference standard in analytical method development or in studies of bacterial resistance. It is available from pharmaceutical suppliers. |
| Molecular Formula |
C22H24N6O9S3
|
|---|---|
| Molecular Weight |
612.6558
|
| Exact Mass |
612.076
|
| CAS # |
98753-19-6
|
| Related CAS # |
Cefpirome;84957-29-9
|
| PubChem CID |
11954008
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
198-202ºC
|
| LogP |
0.294
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
40
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S1C([H])([H])C(C([H])([H])[N+]2=C([H])C([H])=C([H])C3C([H])([H])C([H])([H])C([H])([H])C2=3)=C(C(=O)[O-])N2C([C@]([H])([C@@]12[H])N([H])C(/C(/C1=C([H])SC(N([H])[H])=N1)=N\OC([H])([H])[H])=O)=O.S(=O)(=O)(O[H])O[H]
|
| InChi Key |
RKTNPKZEPLCLSF-QHBKFCFHSA-N
|
| InChi Code |
InChI=1S/C22H22N6O5S2.H2O4S/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27;1-5(2,3)4/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32);(H2,1,2,3,4)/b26-15-;/t16-,20-;/m1./s1
|
| Chemical Name |
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~1 mg/mL (~1.63 mM)
DMSO : ~1 mg/mL (~1.63 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6322 mL | 8.1611 mL | 16.3223 mL | |
| 5 mM | 0.3264 mL | 1.6322 mL | 3.2645 mL | |
| 10 mM | 0.1632 mL | 0.8161 mL | 1.6322 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
